Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.

Wan H, Xu N, Wang L, Liu Y, Fatahi S, Sohouli MH, Guimarães NS

Diabetology & metabolic syndrome6 Nov 2024Cited by 8 (Europe PMC)

PMID39508238PMCIDPMC11542446DOI10.1186/s13098-024-01501-xPepBankPUB-39508238

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomized trials in people with overweight or obesity, survodutide injection reduced body weight versus control (WMD -8.33 kg).
In plain wordsIn a pooled analysis of trials, survodutide injections lowered body weight more than the control group.
Peptide
Survodutide
Outcome
DecreaseBody weight (pooled WMD)
Study
n = 1,029
Comparator
Control group
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injectableAs given in this study (human).
Measurements
WMD
−8.33 kg
weight
Source sentences
Summary
The Findings from 18 treatment arms with 1029 participants indicated significant reductions in weight (WMD: -8.33 kg; 95% CI: -10.80, -5.86; I² = 99.6%)
1 context sentence(design, population, supporting numbers)
Summary · context
In order to identify all randomized controlled trials that investigated the effects of Survodutide on factores related to obesity, a systematic search was conducted in the original databases using predefined keywords until August 2024.
Report a problemFND-3950823801
02HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomized trials, survodutide injection reduced BMI versus control (WMD -4.03 kg/m2).
In plain wordsIn a pooled analysis of trials, survodutide injections lowered body mass index more than the control group.
Peptide
Survodutide
Outcome
DecreaseBody mass index (pooled WMD)
Study
n = 1,029
Comparator
Control group
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injectableAs given in this study (human).
Measurements
WMD
−4.03 kg/m2
BMI
Source sentences
Summary
body mass index (BMI) (WMD:-4.03 kg/m²; 95% CI: -4.86, -3.20; I2 = 72.7%)
1 context sentence(design, population, supporting numbers)
Summary · context
In order to identify all randomized controlled trials that investigated the effects of Survodutide on factores related to obesity, a systematic search was conducted in the original databases using predefined keywords until August 2024.
Report a problemFND-3950823802
03HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomized trials, survodutide injection reduced waist circumference versus control (WMD -6.33 cm).
In plain wordsIn a pooled analysis of trials, survodutide injections reduced waist size more than the control group.
Peptide
Survodutide
Outcome
DecreaseWaist circumference (pooled WMD)
Study
n = 1,029
Comparator
Control group
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injectableAs given in this study (human).
Measurements
WMD
−6.33 cm
waist circumference
Source sentences
Summary
waist circumferences (WC) (WMD: -6.33 cm; 95% CI: -8.85 to -3.81; I² = 99.5%) following the Survodutide injection compared to the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
In order to identify all randomized controlled trials that investigated the effects of Survodutide on factores related to obesity, a systematic search was conducted in the original databases using predefined keywords until August 2024.
Report a problemFND-3950823803
04HumanSystematic reviewEfficacy outcome
In the subgroup analysis, interventions longer than 16 weeks were associated with larger reductions in weight and waist circumference with survodutide.
In plain wordsIn pooled trials, longer survodutide treatment (over 16 weeks) was linked to larger drops in weight and waist size.
Peptide
Survodutide
Outcome
DecreaseWeight and waist circumference by intervention duration (subgroup)
Study
n: not reported in source
Comparator
Control group
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injectable · more than 16 weeksAs given in this study (human).
Source sentences
Summary
Subgroup analysis reveals that longer interventions (more than 16 weeks) and higher doses (more than 2 mg/week) of Survodutide are associated with more significant reductions in weight and WC. These results were also observed in the meta-regression analysis.
1 context sentence(design, population, supporting numbers)
Summary · context
In order to identify all randomized controlled trials that investigated the effects of Survodutide on factores related to obesity, a systematic search was conducted in the original databases using predefined keywords until August 2024.
Report a problemFND-3950823804
05HumanSystematic reviewEfficacy outcome
In the subgroup analysis, doses above 2 mg/week were associated with larger reductions in weight and waist circumference with survodutide.
In plain wordsIn pooled trials, higher survodutide doses (over 2 mg a week) were linked to larger drops in weight and waist size.
Peptide
Survodutide
Outcome
DecreaseWeight and waist circumference by dose (subgroup)
Study
n: not reported in source
Comparator
Control group
Outcome group
Body weight · Metabolic and weight
Studied dose
more than 2 mg/week · injectableAs given in this study (human).
Source sentences
Summary
Subgroup analysis reveals that longer interventions (more than 16 weeks) and higher doses (more than 2 mg/week) of Survodutide are associated with more significant reductions in weight and WC. These results were also observed in the meta-regression analysis.
1 context sentence(design, population, supporting numbers)
Summary · context
In order to identify all randomized controlled trials that investigated the effects of Survodutide on factores related to obesity, a systematic search was conducted in the original databases using predefined keywords until August 2024.
Report a problemFND-3950823805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.